drugset / Trial / NCT05182164
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.
Timeline
- Start
- 2022-04-25
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |